VRDN250117C20000
- 0.65
- +0.20+44.44%
Viridian Therapeutics Newsroom
Wells Fargo Downgrades Viridian Therapeutics(VRDN.US) to Hold Rating, Cuts Target Price to $27
Wells Fargo Downgrades Viridian Therapeutics to Equal-Weight, Announces $27 Price Target
Buy Rating Reaffirmed for Viridian Therapeutics: Promising Phase 3 Results for Veligrotug in TED Treatment
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $47
TD Cowen Maintains Viridian Therapeutics(VRDN.US) With Buy Rating
TD Cowen Remains a Buy on Viridian Therapeutics (VRDN)
Oppenheimer Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $28
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $34 to $61
Viridian Therapeutics (VRDN) Gets a Buy From Oppenheimer
Viridian Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $34 Price Target
Viridian Therapeutics' Veligrotug: Promising Phase 3 Results and Strong Buy Rating
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), DocGo (DCGO) and Alkermes (ALKS)
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $44
RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $44 Price Target
Viridian Therapeutics Analyst Ratings
Needham Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $38
Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target
TD Cowen Initiates Viridian Therapeutics(VRDN.US) With Buy Rating
Viridian Therapeutics: Buy Rating Due to Promising TED Therapy and Market Potential